Onchocerciasis Market

Market Overview:

The onchocerciasis market reached a value of USD 412.3 Million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 1,043.1 Million by 2035, exhibiting a growth rate (CAGR) of 8.86% during 2025-2035.

The onchocerciasis market has been comprehensively analyzed in IMARC's new report titled "Onchocerciasis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Onchocerciasis is a disease caused by a parasitic worm called Onchocerca volvulus. The parasite can spread to humans through repeated bites from infected Simulium blackflies. Flies breed in fast-flowing rivers and streams in remote, tropical agricultural regions. The condition can cause serious skin and visual problems, like blindness. Some common indications of the ailment include intense itching, swelling, inflammation, depigmentation, hyperpigmentation, rash, nodules under the skin, low vision, clouding of the cornea, light sensitivity, lesions on the eyes, glaucoma, eye pain, etc. In some cases, onchocerciasis has been associated with childhood epilepsy and nodding syndrome. Diagnosing this illness commonly involves a comprehensive clinical assessment and eye examination. Furthermore, the polymerase chain reaction (PCR) of the skin snip can be used to detect the parasite's DNA, potentially improving sensitivity. The healthcare provider may also conduct a skin snip biopsy, in which a small, bloodless skin snip is taken from areas like the iliac crest, scapula, or lower extremities to examine it under a microscope and identify microfilariae.

The escalating cases of parasitic infections, in which the parasite transmits in humans through the bites of infected blackflies that breed near fast-flowing rivers and streams, are primarily driving the onchocerciasis market. In addition to this, the inflating utilization of anti-parasitic drugs, like ivermectin, since it kills the microfilariae, the immature worms that cause the skin and eye problems associated with the disease, is also creating a positive outlook for the market. Moreover, the widespread adoption of corticosteroids to help manage inflammatory reactions in onchocerciasis, particularly the Mazzotti reaction, which occurs after ivermectin treatment as dying microfilariae trigger immune responses, is further bolstering the market growth. Apart from this, the rising usage of nodulectomy on account of its numerous benefits, like reduced disease progression and improved patient outcomes, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of CRISPR gene-editing techniques for targeting Onchocerca volvulus genes to disrupt worm survival and reproduction is expected to drive the onchocerciasis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the onchocerciasis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for onchocerciasis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the onchocerciasis market in any manner.

Drugs:

Ivermectin is an anti-parasite medication used to treat onchocerciasis. Ivermectin binds specifically and strongly to glutamate-gated chloride ion channels in invertebrate muscle and nerve cells of the microfilaria. This binding increases the permeability of the cell membrane to chloride ions, resulting in hyperpolarization and paralysis of the parasite. Ivermectin is also thought to function as an agonist of the neurotransmitter gamma-aminobutyric acid (GABA), affecting GABA-mediated central nervous system (CNS) neurosynaptic communication. The drug may also affect the normal intrauterine development of O. volvulus microfilariae and prevent their escape from the uteri of pregnant female worms.

Emodepside targets Onchocerca volvulus by activating latrophilin-like receptors, leading to paralysis and death of adult worms and microfilariae. It enhances potassium channel (SLO-1) activity, disrupting neurotransmission and muscle function in the parasite. Emodepside is effective against both adult worms and larvae, making it a promising macrofilariacidal treatment for onchocerciasis, potentially reducing the need for repeated treatments.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the onchocerciasis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the onchocerciasis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current onchocerciasis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the onchocerciasis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the onchocerciasis market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the onchocerciasis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of onchocerciasis across the seven major markets?
• What is the number of prevalent cases (2019-2035) of onchocerciasis by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of onchocerciasis by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with onchocerciasis across the seven major markets?
• What is the size of the onchocerciasis patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of onchocerciasis?
• What will be the growth rate of patients across the seven major markets?

Onchocerciasis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for onchocerciasis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the onchocerciasis market?
• What are the key regulatory events related to the onchocerciasis market?
• What is the structure of clinical trial landscape by status related to the onchocerciasis market?
• What is the structure of clinical trial landscape by phase related to the onchocerciasis market?
• What is the structure of clinical trial landscape by route of administration related to the onchocerciasis market?